Clinical Trial

Disease: Relapsed or Refractory Large B Cell Lymphoma, LBCL, (NCT05714345)

Disease info:

B cell lymphoma refers to types of Non-Hodgkin lymphoma that are characterised by abnormalities of the "B cells" (a type of white blood cell that makes antibodies to help fight infection). B cell lymphoma may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms.

Diffuse large B-cell lymphoma (DLBCL), a form of Non-Hodgkin lymphoma, is the most common blood cancer. Lymphomas occur when cells of the immune system, known as B lymphocytes, grow and multiply uncontrollably. DLBCL occurs mostly in adults and is a fast-growing (aggressive) lymphoma. It can start in the lymph nodes or outside of the lymphatic system in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain. Often, the first sign of DLBCL is a painless rapid swelling in the neck, armpit, abdomen, or groin caused by enlarged lymph nodes. For some people, the swelling may be painful. Other symptoms include night sweats, unexplained fevers, and weight loss.

Non-Hodgkin lymphoma (also known as Non-Hodgkin's lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in a type of white blood cells called lymphocytes, which are part of the body’s immune system. NHL is a term that's used for many different types of lymphoma that all share some of the same characteristics. NHL usually starts in lymph nodes or other lymph tissue, but it can sometimes affect the skin. 

Relapsed refers to when a patient has received active treatment, went off treatment and then the disease came back, whereas refractory refers to disease that is progressing despite active treatment.

DLBCL makes up approximately 40% of NHL cancers. NHL accounts for about 4% of all cancers in the U.S. The American Cancer Society estimates 80,550 people will be diagnosed with NHL in 2023.
Official title:
A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With ALLO-647, Fludarabine, and Cyclophosphamide, vs. Fludarabine and Cyclophosphamide Alone, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy


Allogene Therapeutics

Phone: 415-604-5696



United States, Florida
University of Florida Health Shands Cancer Hospital, Gainesville, Florida, United States, 32608

United States, Georgia 
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States, 30322

United States, Illinois 
University of Illinois Hospital & Health Sciences System, Chicago, Illinois, United States, 60612

United States, Indiana 
Indiana Blood & Marrow Transplantation, Indianapolis, Indiana, United States, 46237

United States, Kentucky
University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, United States, 40202

United States, New Jersey 
Astera Cancer Care - East Brunswick, New Brunswick, New Jersey, United States, 08816

United States, North Carolina 
Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States, 27157

United States, Ohio 
University of Cincinnati Health Barett Cancer Center, Cincinnati, Ohio, United States, 45219

United States, South Carolina 
Prisma Health Cancer Institute-Eastside, Greenville, South Carolina, United States, 29615

Salzburg Cancer Research Institute, Salzburg, Austria, 5020

Universitair Ziekenhuis Brussel, Brussel, Belgium, 1090

Study start:
Mar. 31, 2023
70 participants
Gene editing method:
Delivery method:
- Ex-vivo
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active recruiting


The purpose of the EXPAND study is to assess the safety and clinical efficacy of ALLO-647 combined with fludarabine and cyclophosphamide compared to fludarabine and cyclophosphamide alone in a lymphodepletion regimen prior to ALLO-501A CAR T therapy in adults with relapsed or refractory large B-cell lymphoma

Last updated: Jan. 16, 2024
Search CRISPR Medicine